Reactogenicity, Safety and Immunogenicity of a Live Monovalent А/17/Hong Kong/2017/75108 (H7N9) Influenza Vaccine
This is a single center phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Hong Kong/2017/75108 (H7N9) influenza vaccine in healthy male and female adults, 18 through 49 years of age.
100 Clinical Results associated with Joint Stock Company Microgen, Russia
0 Patents (Medical) associated with Joint Stock Company Microgen, Russia
100 Deals associated with Joint Stock Company Microgen, Russia
100 Translational Medicine associated with Joint Stock Company Microgen, Russia